[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"connective-tissue-diseases\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:connective-tissue-diseases":27},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,17,0,[8,53,80,107,133,157,186,216,240,267,291,325,355,381,404,426,464],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":13,"acronym":4,"eligibilityCriteria":14,"healthyVolunteers":15,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":22,"briefSummary":24,"conditions":25,"keywords":33,"overallStatus":40,"whyStopped":4,"lastUpdateSubmitDate":41,"lastUpdatePostDateStruct":42,"startDateStruct":45,"completionDateStruct":47,"leadSponsor":49,"locationsCount":52},"100551076","the-genetics-navigator-evaluating-a-digital-platform-for-genomics-health-services-100551076",false,"NCT06455384","The Genetics Navigator: Evaluating a Digital Platform for Genomics Health Services","Inclusion:\n\n* Adult patients (18 years of age or older) who are referred to participating clinicians at Mount Sinai Hospital for clinical genetic testing.\n* Parents\u002Flegal guardians (18 years of age or older) of pediatric patients who are referred to participating clinicians at SickKids for clinical genetic testing.\n\nExclusion:\n\n* Known not to be eligible for clinical genetic testing in Ontario\n* Requires urgent clinical genetic testing or prenatal genetic testing\n* Not fluent in English (speaking and reading)",true,"ALL","18 Years",{"count":19,"type":20},170,"ESTIMATED","INTERVENTIONAL",[23],"NA","Genetic testing (GT) (including targeted panels, exome and genome sequencing) is increasingly being used for patient care as it improves diagnosis and health outcomes. In spite of these benefits, genetic testing is a complex and costly health service. This results in unequal access, increased wait times and inconsistencies in care. The use of e-health tools to support genetic testing delivery can result in a better patient experience and reduced distress associated with waiting for results and empower patients to receive and act on medical results. We have previously developed and tested an interactive, adaptable and patient-centred digital decision support tool (Genetics ADvISER) to be used for genetic testing decision making, and have now developed the Genetics Navigator (GN), a patient-centred e-health navigation platform for end-to-end genetic service delivery. The objective of this study is to evaluate the effectiveness of the GN in an RCT in reducing distress with patients and parents of patients being offered genetic testing. Results of this trial will be used to establish whether the GN is effective to use in practice. If effective, GN could fill a critical clinical care gap and improve health outcomes and service use by reducing counselling burden as well as overuse, underuse and misuse of services. These are concerns policy makers seek to address through the triple aims of health care1. This study represents a significant advance in personalized health by assessing the effectiveness of this novel, comprehensive e-health platform to ultimately improve genetic service delivery, accessibility, patient experiences, and patient outcomes.",[26,27,28,29,30,31,32],"Cardiac Conditions","Connective Tissue Diseases","Retinal Disease","Epilepsy in Children","Neurodevelopmental Disorders","Cancer","Polyposis",[34,35,36,37,38,39],"Genomic Sequencing","Randomized Controlled Trial","Clinical Utility","Personal Utility","Decision Aid","Incidental Findings","RECRUITING","2026-06-19",{"date":43,"type":44},"2026-06-24","ACTUAL",{"date":46,"type":44},"2025-10-28",{"date":48,"type":20},"2027-07",{"name":50,"class":51},"Unity Health Toronto","OTHER",3,{"id":54,"slug":55,"hasResults":11,"nctId":56,"briefTitle":57,"officialTitle":58,"acronym":4,"eligibilityCriteria":59,"healthyVolunteers":11,"sex":16,"minAge":60,"maxAge":61,"enrollmentInfo":62,"targetDuration":4,"studyType":21,"phases":64,"briefSummary":67,"conditions":68,"keywords":4,"overallStatus":40,"whyStopped":4,"lastUpdateSubmitDate":70,"lastUpdatePostDateStruct":71,"startDateStruct":73,"completionDateStruct":75,"leadSponsor":77,"locationsCount":79},"100560241","phase-1-adscs-therapy-in-patients-with-ctd-ild-100560241","NCT06574581","ADSCs Therapy in Patients With CTD-ILD","Allogenic Adipose Tissue Derived-MSCs Therapy in Patients With Connective Tissue Diseases-associated Interstitial Lung Disease(CTD-ILD): Phase I\u002FIIa Clinical Trial","Inclusion Criteria:\n\n1. Adult subjects aged between 20 and 80 years who meet the diagnostic criteria for connective tissue diseases such as dermatomyositis, polymyositis, scleroderma, systemic lupus erythematosus, rheumatoid arthritis, or Sjogren's syndrome.\n2. Subjects with refractory or progressive fibrotic interstitial lung disease: Subjects have been treated with steroids and potent immunosuppressants for more than 24 months with continued deterioration of lung function or lung lesions on CT scan (defined as a forced vital capacity (FVC) decline of more than 10% from baseline, an FVC decline of 5-10% with a diffusing capacity for carbon monoxide (DLCO) decline of more than 15% from baseline, or enlargement of lung lesions on CT scan) ; Or subjects with rapidly progressive interstitial lung disease: treated with high-dose steroids (above 0.8 mg\u002Fkg\u002Fday) and potent immunosuppressants for more than 3 months with continued deterioration of lung function or lung lesions on CT scan (defined as an FVC decline of more than 5% from baseline, a DLCO decline of more than 10% from baseline, or enlargement of lung lesions on CT scan); subjects with rapidly worsening condition: Onset of pulmonary symptoms within one month, gradual worsening of dyspnea and decreased blood oxygen levels, or enlargement of lung lesions.\n3. Subjects must have a well-established family support system confirmed by interviews with the principal investigator and social worker.\n4. Negative high-sensitivity urine pregnancy test before the trial.\n5. Agree to use effective contraceptive measures during the trial (e.g., taking contraceptive pills or using intrauterine devices one month before the trial).\n\nExclusion Criteria:\n\n1. Subjects who are unwilling to sign the informed consent form after detailed explanation by the physician.\n2. Patients younger than 20 or older than 80 years who show improvement in lung function or lung lesions on CT scan after 6 months of treatment with steroids and immunosuppressants.\n3. Women who are pregnant or breastfeeding, and women of childbearing age who do not use contraception.\n4. Subjects with abnormal liver function (serum GOT and GPT levels more than twice the upper limit of 40 units, except those caused by inflammatory myopathy) or poor kidney function (serum creatinine levels exceeding 1.4 units).\n5. Subjects with immune deficiencies such as HIV\u002FAIDS or other specific conditions (e.g., those diagnosed with notifiable infectious diseases as per Ministry of Health announcements).","20 Years","80 Years",{"count":63,"type":20},16,[65,66],"PHASE1","PHASE2","Connective tissue disease (CTD), an autoimmune and inflammatory disease, usually accompanied by lung interstitial\u002Falveolar inflammation and fibrosis (so called interstitial lung disease, ILD). The prevalence and mortality rate of CTD-ILD increase in recent several years. Although the use of corticosteroids and strong immunosuppressants can improve ILD in some patients with CTD, progressive lung fibrosis which needs lung transplantation and results in respiratory failure, even with mortality is observed. Currently, stem cell therapy is a breakthrough in the treatment of CTD-ILD, and the effective therapy with stem cells for patients with ILD have been reported.",[27,69],"Interstitial Lung Disease","2026-05-11",{"date":72,"type":44},"2026-05-13",{"date":74,"type":44},"2024-08-20",{"date":76,"type":20},"2027-11-30",{"name":78,"class":51},"China Medical University Hospital",1,{"id":81,"slug":82,"hasResults":11,"nctId":83,"briefTitle":84,"officialTitle":85,"acronym":86,"eligibilityCriteria":87,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":88,"enrollmentInfo":89,"targetDuration":4,"studyType":21,"phases":91,"briefSummary":92,"conditions":93,"keywords":94,"overallStatus":40,"whyStopped":4,"lastUpdateSubmitDate":98,"lastUpdatePostDateStruct":99,"startDateStruct":101,"completionDateStruct":103,"leadSponsor":105,"locationsCount":79},"100634588","early-recognition-of-progressive-lung-fibrosis-in-systemic-rheumatic-diseases-100634588","NCT07541638","Early Recognition of Progressive Lung Fibrosis in Systemic Rheumatic Diseases","Early Recognition of Progressive Lung Fibrosis in Systemic Rheumatic Diseases: a Characterization of the Pulmonary Environment Through Extracellular Vesicles, Advanced and Functional Imaging","COOPERATION1","Inclusion Criteria:\n\n* Female and male aged between 18 and 75 years.\n* Signature of informed consent\n* A clinical diagnosis of SSc, RA, SS, IIM, or UCTD that must adhere to internationally accepted classification criteria \\[Aletha 2010, Van Der Hoogen 2013, Lundberg 2017, Shiboski 2016, Bottai 2017, Antunes 2019\\].\n* A high risk of ILD based on autoantibody profile, specifically: anti-Scl70+ or anti-RNAPIII+ for SSc, anti-CCP+ and\u002For RF+ for RA, anti-RoSSA+ and anti-LaSSB+ for primary SS, anti-synthetase+ for IIM. For UCTD patients, the enrollment criteria will be adapted to match those of Interstitial Pneumonia with Autoimmune Features (IPAF) \\[Fernandes 2019\\], with patients exhibiting one clinical feature of CTD and one serological domain criterion (e.g., ANA positive with nucleolar pattern, RF and anti-CCP positivity, anti-RoSSA and anti-LaSSB positivity, anti-Scl70 positivity) while not meeting the classification criteria for any other CTD.\n* Evidence of ILD based on an HRCT documenting the presence of interstitial changes involving at least 10% of the parenchyma within the previous 6 weeks. An HRCT scan completely negative for ILD changes performed up to 6 weeks before enrollment will be evaluated for the group of CTD patients without ILD.\n* Either naive to immunosuppressants or having been on a stable immunosuppressive regimen for the three months preceding blood collection for EV characterization. Treatment with rituximab must be not administered in the previous 24 weeks.\n\nExclusion Criteria:\n\n* Current treatment with corticosteroids \\>10 mg of prednisone.\n* Poor peripheral venus access that would interfere with blood sampling","75 Years",{"count":90,"type":20},200,[23],"Connective tissue diseases (CTDs) cover a broad range of systemic rheumatic disorders characterized by abnormal immune activation, chronic inflammatory response, and fibrosis of internal organs. The most prevalent is interstitial lung disease (ILD), a severe pulmonary complication seen in 10 to 50% of CTDs and a major determinant of disability and death. Prevalence and clinical course of CTD-ILDs vary widely and seem to be independent of treatment. Current screening and prognosis prediction strategies based on clinical variables and auto-antibodies are inadequate, and disease biomarkers are lacking. The research project aims to identify biomarkers of ILD involvement in CTD patients by characterizing the proteome and transcriptome of extracellular vesicles (EVs) isolated from serum. This will be integrated with high-resolution computed tomography (HRCT) using artificial intelligence (AI)-based imaging assessment. These novel biomarkers are expected to address some current limitations of standard laboratory biomarkers and conventional HRCT imaging.\n\nThe investigator will involve a total of 200 CTD patients divided into two equal groups: those with ILD and those without. Serum EVs will be extracted from patient sera and characterized based on proteome and transcriptome content using mass spectrometry analysis and next-generation RNA-sequencing. The investigator will compare CTD patients with and without ILD, and progressive and non-progressive ILD patients according to OMERACT (Outcome Measures in Rheumatology) initiative criteria during a 12-month follow-up. HRCT features analyzed by a commercially available deep learning AI software will also be compared among CTD-ILD patients based on the occurrence of progression during follow-up.\n\nAn advanced approach combining EVs analysis in serum and AI algorithms of HRCT images, and functional fibrosis assessment in vivo, could enhance our understanding of CTD-ILDs pathogenesis.\n\nThe proposal aims to investigate for the first time the EVs proteomic and transcriptomic profile in serum of patients with CTDs to identify possible biomarkers of lung involvement. The integration of circulating EVs biomarkers with clinical phenotype and with advanced imaging technologies will provide novel diagnostic algorithms that early identify patients with lung involvement in CTD and patients at risk of pulmonary progression.",[27,69],[27,95,96,97],"Interstitial lung disease","Extracellular Vesicles","Artificial Intelligence","2026-04-14",{"date":100,"type":44},"2026-04-21",{"date":102,"type":44},"2024-11-07",{"date":104,"type":20},"2026-12-31",{"name":106,"class":51},"Fondazione Policlinico Universitario Agostino Gemelli IRCCS",{"id":108,"slug":109,"hasResults":11,"nctId":110,"briefTitle":111,"officialTitle":111,"acronym":112,"eligibilityCriteria":113,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":114,"targetDuration":4,"studyType":21,"phases":116,"briefSummary":117,"conditions":118,"keywords":119,"overallStatus":40,"whyStopped":4,"lastUpdateSubmitDate":124,"lastUpdatePostDateStruct":125,"startDateStruct":127,"completionDateStruct":129,"leadSponsor":131,"locationsCount":79},"100614706","impact-of-capillaroscopy-in-the-investigation-of-diffuse-interstitial-pneumonias-100614706","NCT07283081","Impact of Capillaroscopy in the Investigation of Diffuse Interstitial Pneumonias","CAPID","Inclusion Criteria:\n\n* Male or female over 18 years of age;\n* Have received a new diagnosis of PID within the last six months, confirmed by a pulmonologist;\n* Have undergone some specific tests within the last six months (Chest CT scan, respiratory function tests (plethysmography and CO transfer capacity measurement, immunological assessment including: screening for FAN, FR, and anti-CCP);\n* French-speaking patient with no comprehension difficulties;\n* Person affiliated with or beneficiary of a social security system;\n* Free, informed, and written consent signed by the participant and the investigator (no later than the day of inclusion and before any examination required by the research).\n\nExclusion Criteria:\n\n* Have previously undergone a capillaroscopy, regardless of the reason;\n* Have a diagnosis or high suspicion of connective tissue disease based on initial clinical and paraclinical evaluation;\n* Have already started one of the following treatments for pulmonary involvement: systemic corticosteroids, immunosuppressive therapy, antifibrotic therapy;\n* Pregnant or breastfeeding women;\n* Patients covered by Articles L 1121-5 to L 1121-8 (persons deprived of their liberty by judicial or administrative decision, minors, adults subject to legal protection measures, or persons unable to give their consent).",{"count":115,"type":20},48,[23],"The investigators hypothesize that in patients with a new diagnosis of Pulmonary Interstitial Disease (PID), adding capillaroscopy to standard care increases the proportion of patients receiving a diagnosis of PID-Connective Tissue Disease (PID-CTD) within the first three months of follow-up, thereby reducing the time to diagnosis and facilitating the implementation of appropriate treatment as quickly as possible. Therefore, To confirm this hypothesis, it is necessary to know the characteristics of capillaroscopy in patients with a new diagnosis of PID.",[69,27],[120,121,122,123],"Pulmonary Interstitial Disease","capillaroscopy","Connective Tissue Disease","diagnosis","2026-03-17",{"date":126,"type":44},"2026-03-20",{"date":128,"type":44},"2026-03-16",{"date":130,"type":20},"2027-03",{"name":132,"class":51},"University Hospital, Bordeaux",{"id":134,"slug":135,"hasResults":11,"nctId":136,"briefTitle":137,"officialTitle":137,"acronym":138,"eligibilityCriteria":139,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":88,"enrollmentInfo":140,"targetDuration":4,"studyType":21,"phases":142,"briefSummary":143,"conditions":144,"keywords":4,"overallStatus":40,"whyStopped":4,"lastUpdateSubmitDate":148,"lastUpdatePostDateStruct":149,"startDateStruct":151,"completionDateStruct":153,"leadSponsor":155,"locationsCount":79},"100524093","phase-2-129-xenon-mri-as-a-biomarker-for-diagnosis-and-response-to-therapy-in-pulmonary-arterial-hypertension-pah-100524093","NCT06104228","129 Xenon MRI as a Biomarker for Diagnosis and Response to Therapy in Pulmonary Arterial Hypertension (PAH)","Xenon PAH Bio","Inclusion Criteria:\n\nArm 1 -IPAH\n\n* Age: 18-75 years\n* WHO functional class 2 or 3\n* Mean pulmonary artery pressures \\> 20 mmHg\n* Pulmonary capillary wedge pressure ≤15 mmHg\n* Pulmonary vascular resistance \\> 2 Wood Units (WU)\n* No other cause identified for PAH\n\nArm 2 -PAH-CTD\n\n* Age: 18-75 years\n* WHO functional class (FC) 2 or 3\n* Mean pulmonary artery pressures \\> 20 mmHg\n* Pulmonary capillary wedge pressure ≤15 mmHg\n* Pulmonary vascular resistance \\> 2 WU\n* Diagnosis of connective tissue disease\n\nExclusion Criteria:\n\n* PH other than Idiopathic PAH or PAH associated with CTD; any conditions that prevent the performance of 129Xe MRI scans will be excluded from the study.",{"count":141,"type":20},20,[66],"The overall study objectives outlined in this study are to derive 129Xe MRI pulmonary vascular biomarker signatures that differentiate common subtypes of PAH and to determine the ability of 129Xe MRI to longitudinally monitor disease progression and response to therapy in PAH, with the aid of additional assessments, such as labs, echocardiography, and six-minute walk distance (6MWD).",[145,146,147,27],"Pulmonary Arterial Hypertension","Idiopathic Pulmonary Arterial Hypertension","Pulmonary Arterial Hypertension Associated With Connective Tissue Disease (Disorder)","2026-02-23",{"date":150,"type":44},"2026-02-24",{"date":152,"type":44},"2024-08-12",{"date":154,"type":20},"2027-03-31",{"name":156,"class":51},"Bastiaan Driehuys",{"id":158,"slug":159,"hasResults":11,"nctId":160,"briefTitle":161,"officialTitle":162,"acronym":4,"eligibilityCriteria":163,"healthyVolunteers":15,"sex":16,"minAge":17,"maxAge":88,"enrollmentInfo":164,"targetDuration":4,"studyType":166,"phases":4,"briefSummary":167,"conditions":168,"keywords":4,"overallStatus":175,"whyStopped":4,"lastUpdateSubmitDate":176,"lastUpdatePostDateStruct":177,"startDateStruct":179,"completionDateStruct":181,"leadSponsor":183,"locationsCount":4},"100618279","skin-autofluorescence-assessment-of-advanced-glycation-end-products-in-rheumatic-diseases-100618279","NCT07329556","Skin Autofluorescence Assessment of Advanced Glycation End Products in Rheumatic Diseases","Evaluation of Advanced Glycation End Products Accumulation in Rheumatic Diseases Using Non-Invasive Skin Autofluorescence Measurements","Inclusion Criteria:\n\n* Age between 18 and 75 years\n* Diagnosis of an inflammatory rheumatic disease (including rheumatoid arthritis, ankylosing spondylitis, psoriatic arthritis, reactive arthritis, connective tissue diseases, Behçet disease, familial Mediterranean fever, or crystal arthropathies), confirmed by a rheumatologist\n* Healthy volunteers without a history of rheumatic or chronic inflammatory disease (for the control group)\n* Ability to undergo non-invasive skin autofluorescence measurement\n* Ability and willingness to provide written informed consent\n\nExclusion Criteria:\n\n* Diagnosis of diabetes mellitus (type 1 or type 2)\n* Chronic kidney disease with estimated glomerular filtration rate (eGFR) \\\u003C 60 mL\u002Fmin\u002F1.73 m²\n* Active malignancy or history of malignancy within the past 5 years\n* Presence of acute infection or acute inflammatory condition at the time of assessment\n* Secondary causes of systemic inflammation unrelated to the underlying rheumatic disease (e.g., uncontrolled endocrine disorders, chronic liver disease)\n* Use of medications known to markedly affect AGE accumulation or skin autofluorescence measurements (e.g., recent high-dose systemic glucocorticoids)\n* Pregnancy or breastfeeding\n* Presence of significant skin conditions (e.g., extensive dermatitis, scars, tattoos, or burns) at the measurement site that may interfere with skin autofluorescence assessment\n* Inability to comply with study procedures or to provide informed consent",{"count":165,"type":20},300,"OBSERVATIONAL","Rheumatic diseases are chronic inflammatory conditions that can lead to long-term tissue damage and increased cardiovascular and metabolic risk. Advanced glycation end products (AGEs) are harmful molecules that accumulate in the body over time and are known to promote inflammation and oxidative stress. Increased AGE burden has been implicated in several chronic diseases; however, its role in rheumatic diseases has not been fully clarified.\n\nThis observational, cross-sectional study aims to evaluate the accumulation of AGEs in patients with various rheumatic diseases compared with healthy individuals. AGE levels will be assessed non-invasively using skin autofluorescence measurements.\n\nBy comparing AGE burden between patients and healthy controls, this study seeks to improve understanding of the potential role of AGEs in the pathophysiology of rheumatic diseases and to explore their usefulness as a non-invasive biomarker in clinical practice.",[169,170,171,172,173,27,174],"Rheumatoid Arthritis (RA","Ankylosing Spondylitis","Psoriatic Arthritis","Reactive Arthritis (ReA)","Crystal Arthropathies","Familial Mediterranean Fever (FMF )","NOT_YET_RECRUITING","2026-01-08",{"date":178,"type":44},"2026-01-09",{"date":180,"type":20},"2026-01-15",{"date":182,"type":20},"2027-04-15",{"name":184,"class":185},"Bursa City Hospital","OTHER_GOV",{"id":187,"slug":188,"hasResults":11,"nctId":189,"briefTitle":190,"officialTitle":191,"acronym":4,"eligibilityCriteria":192,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":193,"targetDuration":4,"studyType":21,"phases":195,"briefSummary":197,"conditions":198,"keywords":199,"overallStatus":40,"whyStopped":4,"lastUpdateSubmitDate":205,"lastUpdatePostDateStruct":206,"startDateStruct":208,"completionDateStruct":210,"leadSponsor":212,"locationsCount":215},"100571158","phase-3-a-study-to-investigate-the-long-term-safety-and-efficacy-of-belimumab-in-adults-with-interstitial-lung-disease-ild-associated-with-systemic-sclerosis-ssc-and-other-connective-tissue-diseases-ctd-blissconnectd-ole-100571158","NCT06716606","A Study to Investigate the Long-term Safety and Efficacy of Belimumab in Adults With Interstitial Lung Disease (ILD) Associated With Systemic Sclerosis (SSc) and Other Connective Tissue Diseases (CTD) (BLISSconneCTD-OLE)","An Open Label Study to Investigate the Long-term Safety and Efficacy of Belimumab in Adults With Interstitial Lung Disease (ILD) Associated With Systemic Sclerosis (SSc) and Other Connective Tissue Diseases (CTD)","Inclusion Criteria:\n\n* Participants with SSc-ILD or other CTD-ILDs that have completed either study 218224 or 221672 through to and including the Week 52 visit and are not considered treatment failure, defined as meeting either of the following criteria:\n\n  * Discontinuation of study medication during study 218224 or 221672 for any reason.\n* Participants with SSc should have an area of uninvolved or mildly thickened skin that, in the opinion of the investigator, would allow subcutaneous (SC) injection at the abdomen or the front, middle region of the thigh.\n* Participant is capable and willing to self-administer the study medication or has a caregiver\u002Fhealthcare professional who is capable and willing to administer the study medication throughout the study.\n* Female participants: A female participant is eligible to participate if she is not pregnant or breastfeeding, and one of the following conditions applies:\n\nIs a woman of non-childbearing potential (WONCBP) or is a woman of childbearing potential (WOCBP) and using a contraceptive method that is highly effective, with a failure rate of less than (\\\u003C)1 percentage (%), during the study treatment period and for at least 4 months after the last dose of study intervention. The investigator should evaluate potential for contraceptive method failure (e.g., non-compliance, recently initiated) in relationship to the first dose of study intervention.\n\n1. A WOCBP must have a negative highly sensitive pregnancy test (urine or serum, as required by local regulations) within 24 hours before the first dose of study intervention.\n2. If a urine test cannot be confirmed as negative (e.g., an ambiguous result), a serum pregnancy test is required. In such cases, the participant must be excluded from participation if the serum pregnancy result is positive.\n3. Additional requirements for pregnancy testing during and after study intervention are located.\n4. The investigator is responsible for review of medical history, menstrual history, and recent sexual activity to decrease the risk for inclusion of a woman with an early undetected pregnancy.\n\n   * Capable of giving signed informed consent which includes compliance with the requirements and restrictions listed in the informed consent form (ICF) and in the protocol.\n\nExclusion Criteria:\n\n* Participants of study 218224 or study 221672 who have discontinued study treatment, prior to Week 52.\n* Participants who have developed clinical evidence of significant, unstable or uncontrolled, acute or chronic diseases not due to SSc or other CTD (i.e, cardiovascular, pulmonary, hematologic, gastrointestinal, hepatic, renal, neurological, malignancy or infectious diseases), or experienced an AE in study 218224 or study 221672 that could, in the opinion of the principal investigator, put the participant at undue risk.\n* Participants who have developed any other medical diseases (eg, cardiopulmonary), laboratory abnormalities, or conditions (eg, poor venous access) that, in the opinion of the investigator could significantly alter the absorption, metabolism, or elimination of drugs; constitutes a risk when taking the study intervention; interferes with the interpretation of data; or it is not safe for the participant to continue on the study.\n* Participants who have been exposed to ionizing radiation in excess of 10 millisievert (mSv) above background over the previous 3 year period as a result of occupational exposure or previous participation in research studies.\n* QT Interval Corrected (QTc) greater than (\\>) 480 millisecond (msec) at Week 52 of parent study 218224 or study 221672.",{"count":194,"type":20},514,[196],"PHASE3","This is an open label extension (OLE) study of an ongoing randomized controlled parent clinical studies 218224 (NCT05878717) and 221672 (NCT06572384) which aim to assess the efficacy and safety of belimumab on reducing the decline in lung function in participants with interstitial lung disease associated with diffuse cutaneous systemic sclerosis (dcSSc-ILD) and interstitial lung disease associated with other connective tissue diseases (CTD-ILD), respectively. The OLE study will describe how well tolerated belimumab will be long term, and whether it might continue to slow progression of lung function decline, slow overall disease progression and improve quality of life.",[27],[200,201,202,95,203,204],"Belimumab","Long-term","Open label extension","Diffuse cutaneous systemic sclerosis","Connective tissue disease","2025-12-02",{"date":207,"type":44},"2025-12-09",{"date":209,"type":44},"2024-12-12",{"date":211,"type":20},"2029-12-27",{"name":213,"class":214},"GlaxoSmithKline","INDUSTRY",10,{"id":217,"slug":218,"hasResults":11,"nctId":219,"briefTitle":220,"officialTitle":221,"acronym":4,"eligibilityCriteria":222,"healthyVolunteers":11,"sex":16,"minAge":4,"maxAge":4,"enrollmentInfo":223,"targetDuration":4,"studyType":166,"phases":4,"briefSummary":225,"conditions":226,"keywords":227,"overallStatus":175,"whyStopped":4,"lastUpdateSubmitDate":231,"lastUpdatePostDateStruct":232,"startDateStruct":234,"completionDateStruct":236,"leadSponsor":238,"locationsCount":79},"100601980","study-for-patients-with-connective-tissue-diseases-who-suffer-from-pleuropulmonary-symptoms-clinically-and-radiologically-100601980","NCT07117552","Study for Patients With Connective Tissue Diseases Who Suffer From Pleuropulmonary Symptoms Clinically and Radiologically","Clinical and Radiological Pattern of Pleuropulmonary Affection in Patients With Connective Tissue Diseases","Inclusion Criteria:\n\n* Patients who have diagnosed as connective tissue disease Presented by pleuropulmonary affection\n\nExclusion Criteria:\n\n* Patients who presented by pleuropulmonary affection due to disease other than connective tissue diseases",{"count":224,"type":20},50,"Study for clinical and radiological presentation of patients with connective tissue diseases who complain from pleuropulmonary symptoms",[27],[228,229,230],"Connective tissue diseases","Pulmonary affection","Pulmonary complications","2025-08-09",{"date":233,"type":44},"2025-08-12",{"date":235,"type":20},"2025-09-01",{"date":237,"type":20},"2025-10-30",{"name":239,"class":51},"Sohag University",{"id":241,"slug":242,"hasResults":11,"nctId":243,"briefTitle":244,"officialTitle":245,"acronym":4,"eligibilityCriteria":246,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":88,"enrollmentInfo":247,"targetDuration":4,"studyType":21,"phases":249,"briefSummary":250,"conditions":251,"keywords":253,"overallStatus":40,"whyStopped":4,"lastUpdateSubmitDate":257,"lastUpdatePostDateStruct":258,"startDateStruct":260,"completionDateStruct":262,"leadSponsor":264,"locationsCount":266},"100515995","phase-2-telitacicept-for-the-treatment-of-connective-tissue-disease-associated-thrombocytopenia-100515995","NCT05998759","Telitacicept for the Treatment of Connective Tissue Disease-associated Thrombocytopenia","A Randomized, Double-blind Placebo-controlled Study of Recombinant Human B Lymphocyte Stimulating Factor Receptor-Fc Fusion Protein for the Treatment of Connective Tissue Disease-associated Thrombocytopenia","Inclusion Criteria:\n\n* Subjects who have been diagnosed with connective tissue disease (CTD)-associated thrombocytopenia. And CTD includes primary Sjögren syndrome (according to the 2002 American College of Rheumatology (ACR)\u002F European League against Rheumatism (EULAR) classification criteria), systemic lupus erythematosus (SLE, according to the 1997 or the 2009 ACR classification criteria), and undifferentiated connective tissue disease (according to the 1999 international classification criteria)\n* Refractory thrombocytopenia defined as:\n\nEither: Failure to maintain sustained remission after treatment by glucocorticoid and at least one immunosuppressant (i.e. cyclophosphamide, cyclosporine, mycophenolate mofetil, azathioprine, tacrolimus, methotrexate, leflunomide and hydroxychloroquine, et al.) Or: Relapse during oral glucocorticoid tapering or after withdrawal\n\n* 50×10\\^9\u002FL\\>PLT\n* anti-nuclear antibody (ANA) positive (≥1:80, any karyotype) detected in the laboratory of each research center\n* Standard therapy should be maintained stable for at least 14 days prior to the first dose of the experimental drug or placebo. Standard therapy refers to the following treatment (monotherapy or in combination): glucocorticoid, hydroxychloroquine, and other immunosuppressants (i.e. cyclophosphamide, cyclosporine, mycophenolate mofetil, azathioprine, tacrolimus, methotrexate and leflunomide, et al.)\n* Signed informed consent form, willing or able to participate in all required study evaluations and procedures\n\nExclusion Criteria:\n\n* Vital organ lethal bleeding (including but not limited to central nervous system bleeding, digestive tract bleeding) at screening, or intracranial bleeding 6 months prior to screening\n* Antiphospholipid syndrome, thrombotic thrombocytopenia purpura, hemolytic uremic syndrome, or thrombocytopenia secondary to other causes (such as sepsis, Epstein-Barr virus infection, cytomegalovirus infection, Corona Virus Disease-19 (COVID-19) infection, drugs, etc.)\n* Hematopoietic system disorders, such as myelodysplastic syndrome, paroxysmal sleep hemoglobinuria, aplastic anemia, leukemia, lymphoma, myelofibrosis and so on\n* Severe cardiovascular system disease, including: unstable or uncontrollable disease or condition affecting the function of the heart (such as angina pectoris, congestive heart failure, uncontrolled hypertension or arrhythmia)\n* Arteriovenous thromboembolism events\n* Receiving antiplatelet or anticoagulant therapy at screening\n* Clinically significant electrocardiogram changes\n* corrected Q-T interval (QTc)\\>450ms for male, QTc\\>470ms for female\n* Severe pulmonary disease, including: unstable or uncontrollable disease or condition affecting respiratory function \\[e.g., diffuse alveolar hemorrhage, severe pulmonary hypertension, severe pulmonary interstitial disease (peripheral blood oxygen saturation \\\u003C92% at rest without oxygen, or forced vital capacity (FVC)\\\u003C50%, or carbon monoxide diffusing capacity (DLCO)\\\u003C50%)\\]\n* Severe kidney disease, including: severe lupus nephritis (urinary protein \\> 6 g\u002F24 hours or endogenous creatinine clearance \\\u003C 30 ml \u002Fmin) 8 weeks prior to randomization, active nephritis requiring current protocol disallowed drugs, severe renal insufficiency requiring hemodialysis or prednisone ≥100mg\u002F day (or equivalent) for ≥14 days\n* SLE or non-SLE related central nervous system disease (including epilepsy, psychosis, organic encephalopathy syndrome, cerebrovascular accident, encephalitis, central nervous system vasculitis) 8 weeks prior to randomization\n* Active hepatitis, a history of severe liver disease. Subjects positive for hepatitis B surface antigen (HBsAg) or antibodies to hepatitis C virus are excluded. As for subjects with antibodies to hepatitis B core antigen (HBcAb), further hepatitis B virus (HBV)-DNA should be tested. If HBV-DNA is negative, subjects could be enrolled; otherwise, subjects should be excluded\n* Abnormal laboratory results (including but not limited to: alanine aminotransferase (ALT) or aspertate aminotransferase (AST)≥3×ULN (upper limit of normal), white blood cell count \\\u003C1.5×10\\^9\u002FL)\n* Subjects with known active infections (e.g., shingles, COVID-19, HIV, active tuberculosis, etc.), and active or recurrent gastrointestinal ulcers\n* Pregnant or lactating women, and subjects with a during plan during the trial\n* Allergic reaction: history of allergic reactions to human biological products\n* Treatment with B cell-targeting agents such as Rituximab or Epratuzumab or Belimumab six months prior to randomization\n* Treatment with tumor necrosis factor (TNF) inhibitors or TNF-receptor blockers six months prior to randomization\n* Participating in clinical trial 28 days or 5 drug half-lives of the investigational agents prior to randomization\n* Received live vaccine 28 days prior to randomization\n* Treatment with unstable dosage of thrombopoietin receptor agonists such as Eltrombopag or Romiplostim 14 days prior to randomization\n* Subjects with depression or suicidal thoughts\n* Previous treatment with telitacicept\n* B cell targeting drug therapy is not tolerated or responsive\n* Investigator considers candidates not appropriating for the study",{"count":248,"type":20},296,[66],"The goal of this clinical trial is to evaluate the efficacy and safety of Telitacicept for the treatment of connective tissue disease-associated thrombocytopenia.",[27,252],"Thrombocytopenia",[27,252,254,255,256],"biological agents","B cell","targeted therapy","2025-05-03",{"date":259,"type":44},"2025-05-06",{"date":261,"type":44},"2023-12-02",{"date":263,"type":20},"2025-12",{"name":265,"class":185},"Beijing Hospital",23,{"id":268,"slug":269,"hasResults":11,"nctId":270,"briefTitle":271,"officialTitle":272,"acronym":4,"eligibilityCriteria":273,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":274,"targetDuration":4,"studyType":21,"phases":276,"briefSummary":277,"conditions":278,"keywords":4,"overallStatus":40,"whyStopped":4,"lastUpdateSubmitDate":282,"lastUpdatePostDateStruct":283,"startDateStruct":285,"completionDateStruct":287,"leadSponsor":289,"locationsCount":79},"100438792","phase-2-avatrombopag-in-the-treatment-of-adult-immune-thrombocytopenia-with-autoantibodies-100438792","NCT04993885","Avatrombopag in the Treatment of Adult Immune Thrombocytopenia With Autoantibodies","Efficacy and Safety of Avatrombopag in the Treatment of Adult Immune Thrombocytopenia With Autoantibodies Fail to Eltrombopag or Herombopag Treatment: a Single-center, Prospective, One-arm Clinical Trial","Inclusion Criteria:\n\n* The patients have provided written informed consent prior to enrollment.\n* Men and women greater than or equal to 18 years of age.\n* Diagnosed as ITP secondary to connective tissue diseases (including but not limited to systemic lupus erythematosus, Sjogren's syndrome and rheumatoid arthritis), primary ITP with positive antinuclear antibody but not up to the diagnostic criteria of connective tissue diseases, primary Evans syndrome, Evans syndrome secondary to connective tissue diseases, and primary ITP with positive Coomb's test but not up to the diagnostic criteria of Evans syndrome.\n* Platelet count\\\u003C30 ×10\\^9\u002FL at screening.\n* Patients who have previously failed to receive Eltrombopag or Herombopag \\[poor efficacy (Eltrombopag 75 mg\u002Fd or Herombopag 7.5 mg\u002FD, at least 4 weeks), or the efficacy cannot be maintained\\], or who have contraindications, can not tolerate or refuse Eltrombopag or Herombopag treatment.\n* Treatment for ITP (including but not limited to glucocorticoids, recombinant human thrombopoietin, and other thrombopoietin receptor agonists other than Avatrombopag) must be completed before enrollment, or the dose must be stable or in a phase of reduction within 2 weeks before enrollment.\n* Effective contraceptive measures will be taken during the clinical trial.\n\nExclusion Criteria:\n\n* Patients with active thyroid disease requiring treatment.\n* Patients with any prior history of arterial or venous thrombosis within 3 months, and with any of the following risk factors: cancer, Factor V Leiden, ATIII deficiency, or patients who are using anticoagulants or antiplatelet drugs at the beginning of screening.\n* Those who had received rituximab within 3 months.\n* Patients who had failed to respond to the previous use of Avatrombopag (40mg once a day for more than 4 weeks).\n* Subjects known to be allergic to Avatrombopag or any of its excipients.\n* Patients who had received splenectomy within 3 months or have splenectomy plan within 3 months.\n* Patients with lupus encephalopathy or lupus nephritis.\n* Patients with cataract.\n* Patients with infectious fever (including but not limited to pulmonary infection) within 1 month or with active infection during screening.\n* Existing hepatitis B virus, hepatitis C virus replication or HIV infection.\n* Severe liver dysfunction (alanine aminotransferase or glutamic oxaloacetic transaminase \\> 3×ULN).\n* Patients with severe cardiac or pulmonary dysfunction.\n* Severe renal damage (creatinine clearance \\\u003C 30 ml\u002Fmin).\n* There are surgical planners during the study.\n* History of psychiatric disorder.\n* Pregnant or lactating women or those planning to be pregnant during the trial.\n* Patients with a history of drug\u002Falcohol abuse (within 2 years before the study).\n* Patients that had participated in other experimental researches within one month before enrollment.\n* Any other circumstances that the investigator considers that the patient is not suitable to participate in the trial.",{"count":275,"type":20},52,[66],"This prospective, open-label, single-center, one-arm clinical trial aims at evaluating the efficacy and safety of avatrombopag in Chinese adult Immune Thrombocytopenia (ITP) patients with autoantibodies fail (due to intolerance or resistance) to eltrombopag or herombopag treatment.",[279,280,281,27],"Immune Thrombocytopenia","Autoantibodies","Evan Syndrome","2025-02-20",{"date":284,"type":44},"2025-02-24",{"date":286,"type":44},"2021-09-01",{"date":288,"type":20},"2025-09-30",{"name":290,"class":51},"Institute of Hematology & Blood Diseases Hospital, China",{"id":292,"slug":293,"hasResults":11,"nctId":294,"briefTitle":295,"officialTitle":296,"acronym":297,"eligibilityCriteria":298,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":299,"targetDuration":4,"studyType":21,"phases":301,"briefSummary":302,"conditions":303,"keywords":309,"overallStatus":40,"whyStopped":4,"lastUpdateSubmitDate":317,"lastUpdatePostDateStruct":318,"startDateStruct":320,"completionDateStruct":321,"leadSponsor":323,"locationsCount":79},"100572392","home-based-clinical-management-of-interstitial-lung-disease-in-systemic-rheumatic-diseases-100572392","NCT06732674","Home Based Clinical Management of Interstitial Lung Disease in Systemic Rheumatic Diseases","A 54-week, Multi-centre, 2-arm, Randomised Controlled Trial to Assess Home Monitoring for Lung Function and Patient Reported Outcome Measurements Vs. Usual Care in RheuMatic Disease-associated Interstitial Lung Disease: the RMD-mILDer Trial","RMD-mILDer","Inclusion Criteria:\n\n* Systemic rheumatic disease (Systemic sclerosis (SSc), rheumatoid arthritis (RA), idiopathic inflammatory myopathies including antisynthetasis syndromes (IIM), mixed connective tissue disease (MCTD) or Sjøgrens disease (SjD)) classifiable by disease-specific classification criteria\n* Diagnosed interstitial lung disease (ILD) on high resolution computed tomography (HRCT) ≥ 1 year prior to randomization, not explained by other diseases or exposures\n* On stable standard of care treatment 6 months prior to randomization\n* Participants must be able to understand and follow trial procedures including completion of questionnaires regarding Patient Reported Outcome measures\n* Participants must have access to the internet, and experience in using smartphones or other electronic devices with internet access\n* Signed informed consent form\n\nExclusion Criteria:\n\n* Severe heart failure with ejection fraction (EF) \\\u003C 30%\n* Chronic renal failure G4 or more (defined by KDIGO) with glomerular filtration rate (eGFR) \\\u003C 30 mL\u002Fmin using Cockroft-Gault formula.\n* End stage lung disease with forced vital capacity (FVC) \\\u003C 50% and\u002For diffusion capacity for carbon monoxide (DLCO) \\\u003C 40% or coexisting severe other lung diseases (e.g. chronic obstructive pulmonary disease, emphysema)\n* Airway obstruction (pre-bronchodilator FEV1\u002FFVC \\\u003C 0.7) (FEV1 is defined as forced expiratory volume in 1 sec)\n* In the opinion of the investigator, other clinically significant pulmonary abnormalities\n* Significant pulmonary hypertension defined by the following: Previous clinical or echocardiographic evidence of significant right heart failure OR history of right heart catheterization showing a cardiac index \\\u003C\u002F= 2 L\u002Fmin\u002Fm2 OR pulmonary hypertension requiring therapy with epoprostenol\u002Ftreprostinil\n* Active treatment for cancer or non-curable cancer\n* Relative contraindications to performing spirometry, as specified in ATS\u002FERS guidelines.\n* Ongoing Prednisolone ≥ 20 mg\u002Fday at inclusion\n* Unable to speak, write and read Norwegian, German or Romanian in the respective country of inclusion.\n* Unable to perform good quality measurements of FVC on the home-device comparable to results on an in-hospital device, after training.\n* Pregnancy or planned pregnancy",{"count":300,"type":20},218,[23],"The RMD-mILDer trial is a home monitoring strategy trial aiming to improve management of interstitial lung disease related to rheumatic diseases applying eHealth technology.\n\nIt is planned as a 2 arm 54 week multi-centre randomised controlled trial to assess outcome of home monitoring with bi-weekly serial forced vital capacity- and patient reported outcome-measurements compared to standard of care with fixed-interval hospital visits in adult patients with rheumatic disease associated interstitial lung diseases.",[304,305,306,307,308,27],"Interstitial Lung Disease with Progressive Fibrotic Phenotype in Diseases Classified Elsewhere","Systemic Sclerosis Pulmonary","Dermatomyositis","Rheumatoid Arthritis","Sjogren Syndrome with Lung Involvement",[310,311,312,313,314,315,306,316],"home monitoring","remote monitoring","interstitial lung disease","rheumatic disease","lung fibrosis","Systemic sclerosis","Sjøgren","2024-12-16",{"date":319,"type":44},"2024-12-19",{"date":317,"type":20},{"date":322,"type":20},"2028-02-28",{"name":324,"class":51},"Oslo University Hospital",{"id":326,"slug":327,"hasResults":11,"nctId":328,"briefTitle":329,"officialTitle":330,"acronym":331,"eligibilityCriteria":332,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":333,"enrollmentInfo":334,"targetDuration":4,"studyType":166,"phases":4,"briefSummary":335,"conditions":336,"keywords":341,"overallStatus":40,"whyStopped":4,"lastUpdateSubmitDate":346,"lastUpdatePostDateStruct":347,"startDateStruct":349,"completionDateStruct":351,"leadSponsor":353,"locationsCount":79},"100570052","precision-diagnosis-and-care-for-families-with-pulmonary-fibrosis-in-ireland-100570052","NCT06702228","Precision Diagnosis and Care for Families With Pulmonary Fibrosis in Ireland","Precision Diagnosis and Care for Families With Pulmonary Fibrosis in Ireland [PRECISE-PF]","PRECISE-PF","Inclusion Criteria:\n\n* Able and willing to give written informed consent.\n* An MDT diagnosis of fibrotic ILD which fall into one of the following three catagories;\n\n  1. Have a multidisciplinary team (MDT) diagnosis of a fibrotic interstitial lung disease, reporting one or more relatives with a fibrotic form of ILD\n  2. Have a MDT diagnosis of IPF in accordance with consensus criteria, ATS, ERS, JRS, ALAT guidelines without a family history of pulmonary fibrosis.\n  3. Meet the American College of Rheumatology\u002FEuropean League Against Rheumatism criteria for rheumatoid arthritis, scleroderma, Sjogren's syndrome, idiopathic inflammatory myopathy and systemic lupus erythematosus.\n\nExclusion Criteria:\n\n* Currently participating in an interventional clinic trial.\n* Change in clinical phenotype from initial radiological diagnosis to screening.\n* Acute or chronic hypersensitivity pneumonitis with consensus criteria (appropriate exposure history, radiological features ± avian and fungal precipitins).\n* Asbestosis (appropriate occupational history and radiological evidence of asbestos exposure)\n* Life expectancy for any disease, including ILD \\\u003C12 months (investigator assessment)\n* Major extrapulmonary physiological restriction (e.g. chest wall abnormality, large pleural effusion)","85 Years",{"count":165,"type":20},"This study aims to improve the understanding of how genes and the environment can influence and cause pulmonary fibrosis. By identifying the presence of genes and other factors that can put people at risk of developing pulmonary fibrosis, the influence these factors have on the progression of the disease can be studied.\n\nInterstitial lung disease (ILD) is the medical term given to a group of lung diseases affecting the same part of the lung, the interstitium, each with similar symptoms. In some of these diseases, inflammation leads to lung scarring, known as fibrosis. Idiopathic Pulmonary Fibrosis (IPF) is one of these diseases; it has a particular pattern on computed tomography (CT) scans. IPF is 'idiopathic' as it is not yet fully understood why it happens. It has a poor prognosis. The average survival time is three to five years after diagnosis. While new antifibrotic drugs offer hope of slowing disease progression, lung transplant is the only cure, and it comes with its significant risks.\n\nAlthough it is not fully understood what causes IPF, it is known that genetic factors significantly increase the risk of developing the disease. Up to a quarter (25%) of people with IPF with a family history appear to have a causative genetic variant. Familial-pulmonary-fibrosis (FPF), the term for people with at least one relative with IPF, may have worse disease when compared to those without a family history. However, this needs more research. Patients with specific genes, telomere-related gene variants, appear to have a greater risk of developing blood disorders from medications given to suppress the body's immune system after a lung transplant.\n\nProgressive pulmonary fibrosis is pulmonary fibrosis where there is irreversible worsening of the disease, worsening of lung function, respiratory symptoms and even early death. It is of growing importance regardless of the cause, whether it be idiopathic, familial or secondary to a connective tissue disease. ILD is increasingly recognised as a complication of connective tissue diseases. It is the leading cause of death in people with systemic sclerosis. The new antifibrotic drugs slow the progression of CTD-ILD. People with progressive pulmonary fibrosis who have a greater than 10% drop over one year in a measure of their lung function, called the forced vital capacity, benefit most from antifibrotic therapy. Early identification of people with progressive disease would allow the commencement of treatment quicker. At-home spirometry may be a way of identifying those who are worsening early.\n\nThis study hypothesises that by improving knowledge of factors that affect disease behaviour and progression and assessing tools for the early identification of progressive disease, such as at-home spirometry and CT scan pattern determination by deep-learning analysis, we can provide 'precision' diagnosis and treatment. It is hoped that this improved understanding will help reduce the clinical risk for people with pulmonary fibrosis and their families.\n\nThis study aims to recruit 300 patients: 100 with IPF, 100 with FPF, and 100 with CTD ILD. Each participant will be followed for one year.\n\nThis observational study aims to help answer a number of questions:\n\n1. What genetic variants cause people to develop ILD, and which increase a person's risk of developing ILD are present in the study population?\n2. How does pulmonary fibrosis behave in people who have a family history of IPF compared to those who do not and in people with CTD-ILD?\n3. Are different types of pulmonary fibrosis more progressive than others i.e. Is pulmonary fibrosis in those with a family history of pulmonary fibrosis more progressive than in those who do not have a family history?\n4. Is the disease in those with a genetic variant known to cause ILD worse than in those who don't have a gene?\n5. Can at-home spirometry help identify people at risk of progressive disease early?\n6. Can deep-learning analysis (AI) be used to find CT scan patterns to predict when pulmonary fibrosis will worsen?",[27,69,337,338,339,340],"Idiopathic Pulmonary Fibrosis","Familial Idiopathic Pulmonary Fibrosis","Pulmonary Fibrosis","Pulmonary Fibrosis Interstitial",[342,343,344,339,345],"Genetic diseases","Diagnosis, Computer-assisted","Early Diagnosis","Idiopathic Interstitial Pneumonias","2024-11-20",{"date":348,"type":44},"2024-11-22",{"date":350,"type":44},"2021-09-28",{"date":352,"type":20},"2028-04-01",{"name":354,"class":51},"Royal College of Surgeons, Ireland",{"id":356,"slug":357,"hasResults":11,"nctId":358,"briefTitle":359,"officialTitle":360,"acronym":4,"eligibilityCriteria":361,"healthyVolunteers":11,"sex":362,"minAge":60,"maxAge":363,"enrollmentInfo":364,"targetDuration":4,"studyType":166,"phases":4,"briefSummary":366,"conditions":367,"keywords":369,"overallStatus":40,"whyStopped":4,"lastUpdateSubmitDate":373,"lastUpdatePostDateStruct":374,"startDateStruct":376,"completionDateStruct":378,"leadSponsor":379,"locationsCount":79},"100433008","the-clinical-features-and-pregnancy-outcomes-of-ctd-patients-100433008","NCT04918524","The Clinical Features and Pregnancy Outcomes of CTD Patients","The Clinical Features and Pregnancy Outcomes of Patients With Connective Tissue Disease :a Prospective Cohort Study","Inclusion Criteria:\n\n* Women who meet the following inclusion criteria will be eligible to participate in the study:\n\n  1. Age between 20-45 years;\n  2. Diagnosed with APS: patients meet the Sydney classification criteria;\n  3. Diagnosed with UCTD: at least one presence of auto-antibodies, including antinuclear antibody (ANA), anti-extractable nuclear antigen (ENA) antibodies, anti-doublestranded DNA (ds-DNA) antibody, antiphospholipid antibody(aPL), and non-criteria aPL (NC-aPL), with at least one symptoms or signs suggesting connective tissue disease(CTD) , while not fulfilling any classification criteria of a defined CTD.\n  4. Participate voluntarily in this study, willing to use medication and follow-up according to treatment plan, and sign informed consent.\n\nExclusion Criteria:\n\n* Women who meet any of the following criteria will be excluded from the study:\n\n  1.Any known etiology of previous pregnancy loss:\n  1. Known paternal, maternal or embryo chromosome abnormality.\n  2. Maternal endocrine dysfunction: corpus luteal insufficiency; polycystic ovarian syndrome; premature ovarian failure (follicle stimulating hormone, FSH ≥20uU\u002FL in follicular phase);\n  3. hyperprolactinemia; diabetes mellitus; other hypothalamic pituitary-adrenal axis abnormality\n  4. Maternal anatomical abnormality: uterine malformation; Asherman syndrome; cervical incompetence; uterine fibrosis more than 5 cm.Vaginal infection.\n  5. Any known severe cardiac, hepatic, renal, hematological or endocrinal diseases:\n\n  2\\. Any active infection: Active infection including V aricella zostervirus(VZV), human immunodeficiency virus (HIV), Human papillomavirus (HPV),syphilis or tuberculosis.\n\n  3\\. Allergic to prednisone, hydroxychloroquine, low-molecular-weight heparin or aspirin.\n\n  4.Disease history as follows:\n  1. Past history of digestive ulcers or upper gastrointestinal hemorrhage.\n  2. Past history of malignancy.\n  3. Past history of epilepsia or psychotic disorders.\n\n  5.Women have been diagnosed with Systemic lupus erythematosus\n\n  6\\. Women who disagree or cannot complete pregnancy and follow-up after delivery.","FEMALE","45 Years",{"count":365,"type":20},126,"Connective tissue disease (CTD) is a common group of autoimmune diseases, mainly including systemic lupus erythematosus (SLE), antiphospholipid syndrome (APS) , and so on. APS is caused by autoimmune disorders that cause recurrent miscarriage, thrombosis, and thrombocytopenia, and often secondary to connective tissue diseases such as SLE. Undifferentiated connective tissue disease (UCTD) is currently considered to be an independent disease in the classification of CTD. And women of childbearing age who suffer UCTD is more common than that in other definite CTDs. Therefore, the impact of the disease flare and the influence of medicine on pregnancy and lactation are important for these patients who may suffer high-risk of abnormal pregnance.",[27,368],"Pregnancy Related",[204,370,371,372],"Pregnancy outcomes","Clinical features","Risk factors","2023-11-16",{"date":375,"type":44},"2023-11-18",{"date":377,"type":44},"2018-09-11",{"date":104,"type":20},{"name":380,"class":51},"Qilu Hospital of Shandong University",{"id":382,"slug":383,"hasResults":11,"nctId":384,"briefTitle":385,"officialTitle":386,"acronym":4,"eligibilityCriteria":387,"healthyVolunteers":15,"sex":16,"minAge":17,"maxAge":88,"enrollmentInfo":388,"targetDuration":60,"studyType":166,"phases":4,"briefSummary":390,"conditions":391,"keywords":393,"overallStatus":175,"whyStopped":4,"lastUpdateSubmitDate":395,"lastUpdatePostDateStruct":396,"startDateStruct":398,"completionDateStruct":400,"leadSponsor":402,"locationsCount":4},"100514609","connective-tissue-disease-patients-with-pulmonary-hypertension-100514609","NCT05980728","Connective Tissue Disease Patients With Pulmonary Hypertension","The Prognostic Value of Biomarker in Connective Tissue Disease Patients With Pulmonary Hypertension","Inclusion Criteria:\n\n* Definite diagnosis of CTD included Systemic lupus erythematosus（SLE） diagnosed according to the 2019 The European Alliance of Associations for Rheumatology（EULAR） criteria, primary Sjogren's syndrome (pSS) defined according to the 2016 American College of Rheumatology(ACR) criteria, Systemic Sclerosis(SSc) defined according to the 2013 ACR criteria, mixed connective tissue disease (MCTD) defined by Sharp criteria, and Rheumatoid Arthritis(RA) defined according 2010 ACR criteria of two or more CTD at the same time were defined as having overlap syndrome (OS). Patients who had clinical and serological manifestations suggestive of systemic autoimmune diseases but did not fulfil the classification criteria for CTD were defined as having undifferentiated CTD (UCTD).\n* PAH was diagnosed by right heart catheterization was defined as mean Pulmonary Artery Pressure (mPAP)\\>20 Millimeters of mercury（mmHg）, Pulmonary Artery Wedge Pressure（PAWP）≤15mmHg, Pulmonary Vascular Resistance（PVR）\\>2 Wood\n\nExclusion Criteria:\n\n* significant interstitial lung disease or chronic obstructive pulmonary disease;\n* left heart disease or congenital heart disease associated with pulmonary hypertension;\n* chronic thromboembolic pulmonary hypertension;\n* portal hypertension;\n* drug or toxin exposure;\n* HIV infection;\n* any other diseases known to be associated with PAH;\n* age\\\u003C18 years.",{"count":389,"type":20},500,"Adult patients with suspected or confirmed Connective Tissue Disease Patients (CTD)With Pulmonary Hypertension(PH)will be recruited. Patients will be approached, consented, have baseline demographics, diagnostics and disease activity measures recorded, and blood taken. The collection of data and biological material will mirror usual clinical practice as far as possible. Subjects will ideally attend further visits at 3, 6 and 12 months to have bloods taken, outcome measures recorded and questionnaires completed.",[27,392],"Pulmonary Hypertension",[394],"prognosis , biomarker, pulmonary hypertension","2023-10-15",{"date":397,"type":44},"2023-10-17",{"date":399,"type":20},"2023-11-01",{"date":401,"type":20},"2030-09-01",{"name":403,"class":51},"The First Affiliated Hospital with Nanjing Medical University",{"id":405,"slug":406,"hasResults":11,"nctId":407,"briefTitle":408,"officialTitle":409,"acronym":410,"eligibilityCriteria":411,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":412,"targetDuration":413,"studyType":166,"phases":4,"briefSummary":414,"conditions":415,"keywords":416,"overallStatus":40,"whyStopped":4,"lastUpdateSubmitDate":417,"lastUpdatePostDateStruct":418,"startDateStruct":420,"completionDateStruct":422,"leadSponsor":424,"locationsCount":79},"100490394","registry-of-pulmonary-arterial-hypertension-associated-with-connective-tissue-diseases-reconnective-100490394","NCT05665556","REgistry of Pulmonary Arterial Hypertension Associated With CONNECTIVE Tissue Diseases (RECONNECTIVE)","REgistry of Pulmonary Arterial Hypertension Associated With CONNECTIVE Tissue Diseases (RECONNECTIVE) at the National Institute of Medical Sciences and Nutrition Salvador Zubirán","RECONNECTIVE","Inclusion Criteria:\n\n* Incident and prevalent patients diagnosed with Group I associated with Connective Tissue Diseases (CTD)\n* Incident and prevalent patients diagnosed with Group IV Pulmonary Arterial Hypertension (PAH) associated with Connective Tissue Diseases (CTD) with evidence of a chronic thromboembolic pulmonary disease by ventilation\u002Fperfusion pulmonary gammagraph or computed tomography pulmonary angiogram with at least three months of total anticoagulation therapy.\n* Patient diagnosed with a connective tissue disease according to the classification criteria of the American College of Rheumatology.\n* Precapillary pulmonary hypertension confirmed by right heart catheterization (RHC): Mean pulmonary arterial pressure (mPAP) \\>20 mm Hg with a pulmonary arterial wedge pressure ≤ 15 mm Hg and Pulmonary vascular resistance (PVR) ≥ 2.0 Wood units\n\nExclusion Criteria:\n\n* Patients who meet the criteria for another group of pulmonary hypertension (Groups II, III or V).",{"count":19,"type":20},"5 Years","The RECONNECTIVE Registry is an observational single center study, focused on the subgroup of precapillary pulmonary hypertension related to connective tissue diseases. All patients will have hemodynamic confirmation by right heart catheterization and will be follow-up for at least 5 years from admission. All patients diagnosed with Group I Pulmonary Arterial Hypertension (PAH) associated with Connective Tissue Diseases (CTD) and Group IV Pulmonary Hypertension (PH) with CTD will be included. The purpose of the registry is to learn and understand the clinical outcomes and natural history of the pulmonary arterial hypertension in this subgroup of patients to improve the medical care and treatment.",[145,27],[145,122],"2023-06-27",{"date":419,"type":44},"2023-06-29",{"date":421,"type":44},"2022-12-15",{"date":423,"type":20},"2027-12",{"name":425,"class":51},"Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran",{"id":427,"slug":428,"hasResults":11,"nctId":429,"briefTitle":430,"officialTitle":431,"acronym":4,"eligibilityCriteria":432,"healthyVolunteers":11,"sex":16,"minAge":363,"maxAge":433,"enrollmentInfo":434,"targetDuration":4,"studyType":21,"phases":436,"briefSummary":438,"conditions":439,"keywords":451,"overallStatus":40,"whyStopped":4,"lastUpdateSubmitDate":455,"lastUpdatePostDateStruct":456,"startDateStruct":458,"completionDateStruct":460,"leadSponsor":462,"locationsCount":79},"100473080","phase-4-percutaneous-needle-fasciotomy---corticosteroid-injection-for-dupuytrens-contracture-100473080","NCT05440240","Percutaneous Needle Fasciotomy +\u002F- Corticosteroid Injection for Dupuytren's Contracture","Percutaneous Needle Fasciotomy (PNF) +\u002F- Corticosteroid Injection for Dupuytren's Contracture (DC) Affecting Metacarpophalangeal Joints (MCP) . A Randomized Controlled Trial","Sufficient correction of metacarpophalangeal (MCP) joint during the PNF treatment, defined as \\\u003C20° passive extension deficit (PED), is a prerequisite for inclusion.\n\nInclusion Criteria:\n\n* Dupuytren contracture (DC) of ≥ 20° PED in MCP joint measured with a goniometer\n* DC of either II-V finger\n* Well-defined\u002Fpalpable cord\n\nExclusion Criteria:\n\n* Legally incapacitated\n* Previous study inclusion with another finger ray\n* Isolated proximal interphalangeal (PIP) or distal interphalangeal (DIP) joint contracture, defined as MCP joint contracture \\\u003C 20° PED regardless of the deficit in the PIP or DIP joint\n* Previous hand surgery of the affected finger for any reason\n* Known allergy to the study medication\n* Anticoagulant therapy (Acetylsalicylic acid is NOT an exclusion criterion)\n* Pregnant or lactation\n* Insulin dependent diabetes mellitus\n* Ongoing systemic infection or local infection at the site of the procedure\n* Rheumatoid arthritis\n* Amyloidosis or mucopolysaccharidosis\n* Unable to communicate, cooperate or participate in follow-up","99 Years",{"count":435,"type":20},400,[437],"PHASE4","Comparing percutaneous needle fasciotomy +\u002F- corticosteroid injection for Dupuytren's contracture affecting metacarpophalangeal joints. A clinician-initiated, multicenter, randomized controlled trial.",[440,441,442,443,444,445,446,447,448,449,450,27],"Dupuytren Contracture","Dupuytren's Disease","Contracture","Joint Diseases","Musculoskeletal Diseases","Fibroma","Neoplasm, Fibrous Tissue","Neoplasms, Connective Tissue","Neoplasms, Connective and Soft Tissue","Neoplasms by Histologic Type","Neoplasms",[452,453,454],"Percutaneous needle fasciotomy","Corticosteroid","Randomized controlled trial","2023-05-15",{"date":457,"type":44},"2023-05-17",{"date":459,"type":44},"2023-01-10",{"date":461,"type":20},"2030-03",{"name":463,"class":51},"Regionshospitalet Silkeborg",{"id":465,"slug":466,"hasResults":11,"nctId":467,"briefTitle":468,"officialTitle":469,"acronym":470,"eligibilityCriteria":471,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":61,"enrollmentInfo":472,"targetDuration":474,"studyType":166,"phases":4,"briefSummary":475,"conditions":476,"keywords":4,"overallStatus":40,"whyStopped":4,"lastUpdateSubmitDate":478,"lastUpdatePostDateStruct":479,"startDateStruct":481,"completionDateStruct":483,"leadSponsor":485,"locationsCount":79},"100369823","connective-tissue-diseases-and-lung-manifestations-100369823","NCT04095351","Connective Tissue Diseases and Lung Manifestations","Connective Tissue Diseases and Lung Manifestations Prospective Trial With Focus on Systemic Sclerosis (Colipris)","Colipris","Inclusion Criteria:\n\n* The inclusion criteria are adult patients (≥18 years) diagnosed with CTD with signed informed consent.\n\nExclusion Criteria:\n\n* Exclusion criteria are patients with a serious co-morbidity interfering with the course of interstitial lung disease or pulmonary hypertension.",{"count":473,"type":20},120,"10 Years","Despite a number of prospective studies already initiated in the past years, the current epidemiology and course of interstitial lung disease (ILD) and pulmonary hypertension (PH) in patients with connective tissue disease (CTD) is still not well defined, particularly regarding its prevalence, incidence and the management of a broad spectrum of disease presentations.\n\nMajor challenges include the identification of patients with progressive disease, the appropriate time point of therapeutic intervention and the underlying driver of disease (inflammatory or pro-fibrotic stimulus or both?).\n\nTo address these issues in Western Austria, a progressive registry of patients with CTD exploring routine clinical and pathophysiological characteristics of ILD and PH will be conducted. This multidisciplinary, prospective and observational registry aims to collect comprehensive clinical data on incidence, prevalence and course of disease regarding all PH and ILD presentations in a real-world setting.",[27,69,477],"Systemic Sclerosis","2020-05-25",{"date":480,"type":44},"2020-05-27",{"date":482,"type":44},"2019-12-09",{"date":484,"type":20},"2034-10-01",{"name":486,"class":51},"Medical University Innsbruck"]